4 articles featuring Limonene
Chemotherapy-induced nausea and vomiting (CINV) remains a primary driver of treatment non-compliance and reduced quality of life. Modern clinical standards are shifting. While traditional anti-emetics serve as the baseline, the $21 billion global supportive care market is increasingly incorporating cannabinoid therapeutics to fill efficacy gaps. Cannabis is now viewed as a strategic component of evidence-based supportive oncology.
Nausea in older adults is rarely a standalone issue. It is often a byproduct of polypharmacy, slowed gastric motility, or recovery from surgery. When dealing with chronic queasiness, the consequences go far beyond simple discomfort; they may lead to malnutrition, dehydration, and a loss of daily independence.
'The munchies'—or clinically, hyperphagia—is a physiological response triggered when exogenous cannabinoids interact with your body’s endocannabinoid system (ECS). By binding to CB1 receptors in the hypothalamus and the olfactory bulb, specific cannabis compounds may influence how your brain perceives hunger, sensory pleasure, and metabolic homeostasis.
Nausea and appetite loss are metabolic disruptions that can halt tissue repair and protein synthesis. Whether triggered by chronic digestive conditions, chemotherapy-induced nausea, or gastric distress, the body may enter a catabolic state, effectively consuming its own resources. Cannabis, when used as a targeted pharmacological tool, may assist in bypassing these hurdles. The key involves using specific chemotypes and precise dosing to modulate the endocannabinoid system (ECS) without triggering the very nausea you aim to suppress.